Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer

ABSTRACT IMscin001 is a two‐part dose‐finding (Phase Ib) and ‐confirmation (Phase III) study to evaluate atezolizumab pharmacokinetics of subcutaneous (SC) compared with intravenous (IV) administration in patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC). The objectives...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	CPT: pharmacometrics and systems pharmacology Ročník 14; číslo 4; s. 726 - 737
Hlavní autoři:	Chan, Phyllis, Liu, Stephanie N., Gosselin, Nathalie, Sauve, Zacharie, Marchand, Mathilde, Lin, Alyse, Herraez‐Baranda, Luis, Zanghi, James, Shearer‐Kang, Esther, Liu, Xiaoyan, Wu, Benjamin, Chanu, Pascal
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States John Wiley & Sons, Inc 01.04.2025 John Wiley and Sons Inc Wiley
Témata:	Abdomen Administration, Intravenous Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - pharmacokinetics Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Carcinoma, Non-Small-Cell Lung - drug therapy Cell death Dose-Response Relationship, Drug Drug development Drug dosages Female Humans Injections, Subcutaneous Lung cancer Lung Neoplasms - drug therapy Male Metastasis Middle Aged Models, Biological Patients Pharmacokinetics Population
ISSN:	2163-8306, 2163-8306
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!